Champions Biotechnology has established a collaboration with Gradalis and Mary Crowley Cancer Research Center (MCCRC) to develop personalized vaccines for cancer patients. Gradalis will work toward the IND that is required to begin administering the individualized vaccine to patients at MCCRC in a Phase I trial.
The team will use Champions Biotechnology’s Biomerk Tumorgraft™ technology, which engineers vaccines based on each patient’s tumor. “The close correlation between Biomerk Tumorgrafts™ and the human tumor they are derived from provide the basis for our predictive preclinical platform,” explains Doug Burkett, Ph.D., president of Champions Biotechnology.
“This technology also enables us, in collaboration with Gradalis, to develop personalized vaccines for cancer patients. Personalized vaccines offer a novel treatment option that is customized to each individual’s unique cancer but can rarely be produced due to insufficient cells from accessible tumor tissue.”